CriticalCentrally acting cough suppressant×Selective irreversible monoamine oxidase B inhibitor
Updated · Methodology
Mechanism
Rasagiline strongly and irreversibly inhibits the enzyme monoamine oxidase (MAO) type B (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA). MAO takes part in the breakdown of catecholamines and serotonin. At the recommended dose rasagiline is relatively selective for MAO-B, but selectivity falls as the dose rises. Inhibition of platelet MAO-B lasts at least one week after the last dose (rasagiline label, US Food and Drug Administration, FDA). Dextromethorphan has mild serotonergic properties and has caused serotonin syndrome together with MAO inhibitors (dextromethorphan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The reported interactions with dextromethorphan involved non-selective MAO inhibitors. Rasagiline itself inhibits MAO, so the European SmPC advises against the combination and the US label contraindicates it (rasagiline SmPC, EMA; rasagiline FDA label). Rasagiline is unlikely to act through liver enzymes: it neither inhibits nor induces the main cytochrome P450 enzymes, including CYP2D6, which breaks down dextromethorphan in the liver (rasagiline SmPC, EMA; dextromethorphan SmPC, AEMPS).
Symptoms
The combination of monoamine oxidase (MAO) inhibitors and dextromethorphan has caused brief episodes of psychosis or bizarre behaviour (rasagiline label, US Food and Drug Administration, FDA). With MAO inhibitors, dextromethorphan has also caused serotonin syndrome with tremor, clonus, myoclonus, overactive reflexes and rigidity, sweating, fever, fast heart rate and breathing, dilated pupils, agitation and confusion (dextromethorphan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Nausea, coma, low blood pressure, leg tremor, muscle spasms, very high fever and high blood pressure may also occur and can lead to heart attack and death (dextromethorphan orodispersible tablet SmPC, AEMPS).
Management
The US rasagiline label contraindicates the combination (US Food and Drug Administration, FDA). So does the Spanish summary of product characteristics (SmPC) for dextromethorphan 3 mg/ml syrup. It rules out dextromethorphan with any monoamine oxidase (MAO) inhibitor, both at the same time and within 2 weeks of stopping it (dextromethorphan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European rasagiline SmPC and two other Spanish dextromethorphan SmPCs are milder: they advise against the combination and recommend avoiding it (rasagiline SmPC, European Medicines Agency, EMA; dextromethorphan SmPCs, AEMPS). Do not take dextromethorphan until at least 14 days after stopping rasagiline (dextromethorphan SmPCs, AEMPS; over-the-counter dextromethorphan FDA label). Rasagiline inhibits MAO-B irreversibly, and inhibition of platelet MAO-B lasts at least one week after the last dose (rasagiline FDA label). In Spain, all dextromethorphan products, including combination cold and flu remedies, are sold without a prescription (AEMPS medicines register). Ask patients who take rasagiline to mention every over-the-counter medicine they use, especially cold remedies (rasagiline FDA label). The European SmPC also advises against nasal decongestants and cold remedies containing ephedrine or pseudoephedrine with rasagiline (rasagiline SmPC, EMA). If serotonin syndrome is suspected, stop dextromethorphan. Benzodiazepines can be used for seizures, and benzodiazepines with external cooling for hyperthermia from serotonin syndrome (dextromethorphan SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- AEMPS: Ficha técnica: Dextrometorfano (nº registro 70997), sección 4.3 (2026)– AEMPS, CIMA, nº registro 70997 (Laitos 3 mg/ml jarabe), revisión 08/2026, sección 4.3
- AEMPS: Ficha técnica: Dextrometorfano, Cinfatos Antitusivo Flas 15 mg comprimidos bucodispersables (nº registro 85817), sección 4.5 (2025)– AEMPS, CIMA, nº registro 85817, revisión 12/2025, secciones 4.3 y 4.5
- FDA: Delsym Cough (dextromethorphan) OTC Drug Facts label (2026)– FDA, DailyMed, Reckitt Benckiser, setid a43d59f9-3a6c-4a7c-b98d-b86d6035f716, revised 05/2026, Drug Facts: Warnings
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.5 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Dextrometorfano, Bisolvon Antitusivo 2 mg/ml jarabe (nº registro 57174), sección 4.5 (2026)– AEMPS, CIMA, nº registro 57174 (Opella Healthcare Spain), revisión 01/2026, secciones 4.3, 4.4, 4.5 y 5.1